Zacks Investment Research cut shares of Amyris (NASDAQ:AMRS) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “

A number of other research analysts have also recently weighed in on AMRS. ValuEngine raised shares of Amyris from a hold rating to a buy rating in a research report on Thursday, June 28th. BidaskClub raised shares of Amyris from a hold rating to a buy rating in a research report on Thursday, June 28th. HC Wainwright reaffirmed a buy rating and set a $15.00 price target on shares of Amyris in a research report on Tuesday, June 26th. Finally, B. Riley set a $10.00 price target on shares of Amyris and gave the company a buy rating in a research report on Wednesday, October 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and an average price target of $9.13.

AMRS opened at $7.70 on Tuesday. The company has a debt-to-equity ratio of -0.24, a quick ratio of 0.38 and a current ratio of 0.42. Amyris has a 1 year low of $2.82 and a 1 year high of $9.28. The company has a market capitalization of $508.54 million, a P/E ratio of -2.73 and a beta of 0.26.

Amyris (NASDAQ:AMRS) last released its earnings results on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). The company had revenue of $24.81 million for the quarter, compared to analyst estimates of $37.52 million. The business’s revenue was down 3.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.32) earnings per share. As a group, equities research analysts anticipate that Amyris will post -1.41 EPS for the current year.

In other Amyris news, insider John Melo sold 22,355 shares of Amyris stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $6.61, for a total transaction of $147,766.55. Following the transaction, the insider now directly owns 748,908 shares of the company’s stock, valued at $4,950,281.88. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Patrick Y. Yang purchased 15,000 shares of Amyris stock in a transaction on Monday, August 13th. The shares were acquired at an average cost of $7.66 per share, for a total transaction of $114,900.00. Following the completion of the transaction, the director now owns 51,932 shares of the company’s stock, valued at $397,799.12. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 50,877 shares of company stock worth $393,161 and have sold 8,824,625 shares worth $54,897,886. Insiders own 21.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Amyris by 3,109.9% during the second quarter. BlackRock Inc. now owns 1,714,555 shares of the biotechnology company’s stock valued at $10,955,000 after purchasing an additional 1,661,141 shares during the period. Millennium Management LLC raised its stake in shares of Amyris by 13.5% during the second quarter. Millennium Management LLC now owns 278,748 shares of the biotechnology company’s stock valued at $1,781,000 after purchasing an additional 33,085 shares during the period. Northern Trust Corp raised its stake in shares of Amyris by 463.6% during the second quarter. Northern Trust Corp now owns 269,022 shares of the biotechnology company’s stock valued at $1,719,000 after purchasing an additional 221,285 shares during the period. Ardsley Advisory Partners raised its stake in shares of Amyris by 25.0% during the second quarter. Ardsley Advisory Partners now owns 125,000 shares of the biotechnology company’s stock valued at $799,000 after purchasing an additional 25,000 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Amyris by 87.7% during the second quarter. Bank of New York Mellon Corp now owns 106,216 shares of the biotechnology company’s stock valued at $678,000 after purchasing an additional 49,628 shares during the period. Institutional investors own 27.90% of the company’s stock.

About Amyris

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Further Reading: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.